Caffeine for Apnea of Prematurity-Sleep (CAP-S) Study (CAP-S)
|ClinicalTrials.gov Identifier: NCT01020357|
Recruitment Status : Completed
First Posted : November 25, 2009
Last Update Posted : December 5, 2014
Apnea of prematurity is a common condition that is usually treated with methylxanthines. Methylxanthines are adenosine receptor blockers that have powerful influences on the central nervous system. However, little is known about the long-term effects of methylxanthines on the developing brain.
The Caffeine for Apnea of Prematurity-Sleep (CAP-S) Study is a sub-study of the main Caffeine for Apnea of Prematurity (CAP) trial, an international placebo-controlled randomized trial of methylxanthine therapy for apnea of prematurity. This sub-study is designed to take advantage of this cohort of ex-premature, 5-7 year old children who were randomized at birth to receive either caffeine or placebo, and are currently receiving detailed neurocognitive and behavioral assessments in the CAP trial.
|Condition or disease||Intervention/treatment||Phase|
|Apnea of Prematurity||Drug: Caffeine citrate injection Drug: placebo||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||201 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Long-Term Effects On Sleep Of Methylxanthine Therapy For Apnea Of Prematurity|
|Study Start Date :||November 2009|
|Actual Primary Completion Date :||July 2013|
|Actual Study Completion Date :||July 2013|
|Active Comparator: caffeine||
Drug: Caffeine citrate injection
Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.
Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.
Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy.
Other Name: CafCit
|Placebo Comparator: placebo||
- Aim 1: The primary outcome is the mean actual sleep time as measured by actigraphy, between subjects who received caffeine vs placebo. [ Time Frame: 5-7 years ]
- Aim 2: The primary outcome is the apnea hypopnea index (AHI) between subjects who received caffeine vs placebo. [ Time Frame: 5-7 years ]
- Aim 3: The primary outcome is the correlation between full-scale IQ from the Wechsler Preschool and Primary Scale of Intelligence (measured in the CAP trial rather than directly from this protocol), sleep time and AHI. [ Time Frame: 5-7 years ]
- Questionnaire data: National Sleep Foundation (NSF) and Pediatric Sleep Questionnaire (PSQ) scores [ Time Frame: 5-7 years ]
- Polysomnography data: Sleep architecture, arousal index, central apnea index, SpO2 and periodic limb movement index. [ Time Frame: 5-7 years ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01020357
|Mercy Hospital for Women|
|Royal Women's Hospital|
|McMaster University Medical Centre|
|Hamilton, Ontario, Canada, L8S 4J9|
|Sunnybrook Health Sciences Centre|
|Toronto, Ontario, Canada, M5S 1B2|
|Principal Investigator:||Carole Marcus, M.B.B.Ch.||University of Pennsylvania|